{
    "pmcid": "10983868",
    "qa_pairs": {
        "How does RFdiffusion contribute to the design of de novo antibodies according to the study?": [
            "By focusing on CDR loops and maintaining the framework structure of a user-specified therapeutic antibody",
            "By predicting the entire antibody sequence from scratch without any structural constraints",
            "By using a database of known antibodies to generate new sequences through random mutations",
            "By simulating the folding process of antibodies in a virtual environment"
        ],
        "What computational methods are highlighted in the study for designing antibodies?": [
            "RFdiffusion and RoseTTAFold2 networks",
            "CRISPR-Cas9 and TALENs",
            "DeepMind's AlphaFold and Cryo-EM",
            "Molecular docking and homology modeling"
        ],
        "What future improvement does the study suggest for enhancing the modeling capabilities of antibody design?": [
            "Integrating newer generative frameworks and including non-protein atoms like glycans",
            "Increasing the resolution of cryo-EM imaging techniques",
            "Developing faster algorithms for sequence alignment",
            "Utilizing larger animal models for antibody testing"
        ],
        "What is one of the challenges mentioned in the study regarding the designed VHHs targeting SARS-CoV-2?": [
            "Modest binding affinities",
            "High production costs",
            "Limited availability of computational resources",
            "Difficulty in expressing the antibodies in yeast"
        ],
        "What validation method is used to confirm the structures of the designed antibodies in the study?": [
            "Cryo-EM",
            "X-ray crystallography",
            "NMR spectroscopy",
            "Mass spectrometry"
        ]
    }
}